Acurx Pharmaceuticals, Inc.
ACXP· Nasdaq
ACXPAcurx Pharmaceuticals, Inc.
Filed Aug 11, 2023 · 10-Q · 42 days after period end · 0001558370-23-014645
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Net Income | -$3.45M | -$2.62M | -$4.00M | -$913.36K |
| EPS Diluted | -$0.28 | -$0.26 | -$0.57 | -$0.15 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acurx Pharmaceuticals, Inc. · CIK 1736243 · Engraved from SEC EDGAR
ended Jun 30, 2023 · filed Aug 11, 2023 · 42 d after period end
